Differences in the epigenetic regulation of cytochrome P450 genes between human embryonic stem cell-derived hepatocytes and primary hepatocytes

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Park, Han Jin ^a,b   Choi, Young Jun ^b,c   Kim, Ji Woo ^b   Chun, Hang Suk ^b   Im, Ilkyun ^a   Yoon, Seokjoo ^b,c   Han, Yong Mahn ^a   Song, Chang Woo ^b,c   Kim, Hyemin ^b  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; CHROMATIN; CYP1A1 PROTEIN, HUMAN; CYP1A2 PROTEIN, HUMAN; CYP1B1 PROTEIN, HUMAN; HISTONE;

ARTICLE; CHROMATIN STRUCTURE; CONTROLLED STUDY; CPG ISLAND; CYP GENE; CYP1A1 GENE; CYP1A2 GENE; CYP1B1 GENE; CYP2D6 GENE; CYP2E1 GENE; DEMETHYLATION; DNA METHYLATION; EMBRYO; EMBRYONIC STEM CELL; EMBRYONIC STEM CELL DERIVED HEPATOCYTE; ENZYME INHIBITION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LIVER CELL; TRANSCRIPTION REGULATION; UPREGULATION; ANTIBODY SPECIFICITY; CELL DIFFERENTIATION; CELL LINE; CHROMATIN; COMPARATIVE STUDY; CYTOLOGY; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HUMAN EMBRYONIC STEM CELL; METABOLISM; PRIMARY CELL CULTURE; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

CELL DIFFERENTIATION; CELL LINE; CHROMATIN; CPG ISLANDS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP1B1; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; HEPATOCYTES; HISTONE DEACETYLASES; HISTONES; HUMAN EMBRYONIC STEM CELLS; HUMANS; ORGAN SPECIFICITY; PRIMARY CELL CULTURE; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84941309262     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132992     Document Type: Article

References (53)

1. Guguen-Guillouzo C, Corlu A, Guillouzo A (2010) Stem cell-derived hepatocytes and their use in toxicology. Toxicology 270:3-9. doi: 10.1016/j.tox.2009.09.019 PMID: 19815049
2. Szkolnicka D, Zhou W, Lucendo-Villarin B, Hay DC (2013) Pluripotentstem cell-derived hepatocytes: potential and challenges in pharmacology. Annu Rev Pharmacol Toxicol 53:147-159. doi: 10.1146/annurev-pharmtox-011112-140306 PMID: 23294308
3. Scott CW, Peters MF, Dragan YP (2013) Human induced pluripotentstem cells and their use in drug discovery for toxicity testing. Toxicol Lett 219:49-58. doi: 10.1016/j.toxlet.2013.02.020 PMID: 23470867
4. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315-1530. doi: 10.1007/s00204-013-1078-5 PMID: 23974980
5. Sjogren AK, Liljevald M, Glinghammar B, Sagemark J, Li XQ, Jonebring A, et al. (2014) Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes. Arch Toxicol 88:1427-1437. doi: 10.1007/s00204-014-1265-z PMID: 24912781
6. Holmgren G, Sjogren AK, Barragan I, Sabirsh A, Sartipy P, Synnergren J, et al. (2014) Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. Drug Metab Dispos 42:1401-1406. doi: 10.1124/dmd. 114.059154 PMID: 24980256
7. Takayama K, Morisaki Y, Kuno S, Nagamoto Y, Harada K, Furukawa N, et al. (2014) Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc Natl Acad Sci USA 111:16772-16777. doi: 10.1073/pnas.1413481111 PMID: 25385620
8. Hannan NR, Segeritz CP, Touboul T, Vallier L (2013) Production of hepatocyte-like cells from human pluripotentstem cells. Nat Protoc 8:430-437. PMID: 23424751
9. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Sakurai F, et al. (2013) 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 34:1781-1789. doi: 10.1016/j.biomaterials.2012.11.029 PMID: 23228427
10. Gieseck RL3rd, Hannan NR, Bort R, Hanley NA, Drake RA, Cameron GW, et al. (2014) Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. PLoS One 9:e86372. doi: 10.1371/journal.pone.0086372 PMID: 24466060
11. Berger DR, Ware BR, Davidson MD, Allsup SR, Khetani SR (2014) Enhancing the functional maturity of iPSC-derived human hepatocytes via controlled presentation of cell-cell interactions in vitro. Hepatology.
12. Kondo Y, Iwao T, Yoshihashi S, Mimori K, Ogihara R, Nagata K, et al. (2014) Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocytelike cells. PLoSOne 9:e104010. doi: 10.1371/journal.pone.0104010 PMID: 25084468
13. Baxter M, Withey S, Harrison S, Segeritz C, Zhang F, Atkinson-Dell R, et al. (2014) Phenotypicand functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J Hepatol.
14. Basma H, Soto-Gutierrez A, Yannam GR, Liu L, Ito R, Yamamoto T, et al. (2009) Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 136:990-999. doi: 10.1053/j.gastro.2008.10.047 PMID: 19026649
15. Kia R, Sison RL, Heslop J, Kitteringham NR, Hanley N, Mills JS, et al. (2013) Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol 75:885-896. doi: 10.1111/j.1365-2125.2012.04360.x PMID: 22703588
16. Hart SN, Cui Y, Klaassen CD, Zhong XB (2009) Three patterns of cytochrome P450 gene expression during liver maturation in mice. Drug Metab Dispos 37:116-121. doi: 10.1124/dmd.108.023812 PMID: 18845660
17. Lee JS, Ward WO, Liu J, Ren H, Vallanat B, Delker D, et al. (2011) Hepatic xenobiotic metabolizing enzyme and transporter gene expression through the life stages of the mouse. PLoS One 6:e24381. doi: 10.1371/journal.pone.0024381 PMID: 21931700
18. Lee JS, Ward WO, Knapp G, Ren H, Vallanat B, Abbott B, et al. (2012) Transcriptional ontogeny of the developing liver. BMC Genomics 13:33. doi: 10.1186/1471-2164-13-33 PMID: 22260730
19. Zhong XB, Leeder JS (2013) Epigenetic regulation of ADME-related genes: focus on drug metabolism and transport. Drug Metab Dispos 41:1721-1724. doi: 10.1124/dmd.113.053942 PMID: 23935066
20. Bird A (2007) Perceptions of epigenetics. Nature 447:396-398. PMID: 17522671
21. Hirota T, Takane H, Higuchi S, Ieiri I (2008) Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. Curr Drug Metab 9:34-38. PMID: 18220569
22. Kacevska M, Ivanov M, Ingelman-Sundberg M (2011) Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther 89:902-907. doi: 10.1038/clpt.2011.21 PMID: 21508940
23. Bonder MJ, Kasela S, Kals M, Tamm R, Lokk K, Barragan I, et al. (2014) Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics 15:860. doi: 10.1186/1471-2164-15-860 PMID: 25282492
24. Weng MK, Natarajan K, Scholz D, Ivanova VN, Sachinidis A, Hengstler JG, et al. (2014) Lineage-specific regulation of epigenetic modifier genes in human liver and brain. PLoS One 9:e102035. doi: 10. 1371/journal.pone.0102035 PMID: 25054330
25. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141. doi: 10. 1016/j.pharmthera.2012.12.007 PMID: 23333322
26. Hankinson O (1995) Thearyl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35:307-340. PMID: 7598497
27. Rowlands JC, Gustafsson JA (1997) Aryl hydrocarbon receptor-mediated signal transduction. Crit Rev Toxicol 27:109-134. PMID: 9099515
28. Xu C, Li CY, Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249-268. PMID: 15832810
29. Jorge-Nebert LF, Jiang Z, Chakraborty R, Watson J, Jin L, McGarvey ST, et al. (2010) Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat 31:27-40. doi: 10.1002/humu.21132 PMID: 19802894
30. Ueda R, Iketaki H, Nagata K, Kimura S, Gonzalez FJ, Kusano K, et al. (2006) A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 69:1924-1930. PMID: 16505155
31. Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, Rane A, et al. (2012) DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie 94:2338-2344. doi: 10.1016/j.biochi.2012.07.013 PMID: 22906825
32. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. (2007) Reversetranscriptase-PCR quantification of mRNA levels from cytochrome (CYP) 1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17:731-742. PMID: 17700362
33. Chang TK, Chen J, Pillay V, Ho JY, Bandiera SM (2003) Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci 71:11-19. PMID: 12520071
34. Stiborova M, Martinek V, Rydlova H, Koblas T, Hodek P (2005) Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett 220:145-154. PMID: 15766589
35. Kawakami H, Ohtsuki S, Kamiie J, Suzuki T, Abe T, Terasaki T (2011) Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci 100:341-352. doi: 10.1002/jps. 22255 PMID: 20564338
36. Beedanagari SR, Taylor RT, Bui P, Wang F, Nickerson DW, Hankinson O (2010) Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes. Mol Pharmacol 78:608-616. doi: 10.1124/mol.110.064899 PMID: 20631054
37. Nakajima M, Iwanari M, Yokoi T (2003) Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7and HeLa cells. Toxicol Lett 144:247-256. PMID: 12927368
38. Tsuchiya Y, Nakajima M, Yokoi T (2003) Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J Biochem 133:583-592. PMID: 12801909
39. Tekpli X, Zienolddiny S, Skaug V, Stangeland L, Haugen A, Mollerup S (2012) DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int J Cancer 131:1509-1516. doi: 10.1002/ijc.27421 PMID: 22213191
40. Ghotbi R, Gomez A, Milani L, Tybring G, Syvanen AC, Bertilsson L, et al. (2009) Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 9:208-217. doi: 10.1038/tpj.2009.4 PMID: 19274061
41. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874. PMID: 16357870
42. Hagarman JA, Motley MP, Kristjansdottir K, Soloway PD (2013) Coordinate regulation of DNA methylation and H3K27me3 in mouse embryonic stem cells. PLoS One 8:e53880. doi: 10.1371/journal.pone. 0053880 PMID: 23326524
43. Czekaj P, Wiaderkiewicz A, Florek E, Wiaderkiewicz R (2005) Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta. Arch Toxicol 79:13-24. PMID: 15448981
44. Rich KJ, Boobis AR (1997) Expression and inducibility of P450 enzymes during liver ontogeny. Microsc Res Tech 39:424-435. PMID: 9408909
45. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T (1991) Expression of CYP2D6 in developing human liver. Eur J Biochem 202:583-588. PMID: 1722149
46. Vieira I, Sonnier M, Cresteil T (1996) Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238:476-483. PMID: 8681961
47. Hasler JA (1999) Pharmacogenetics of cytochromes P450. Mol Aspects Med 20:12-24, 25-137. PMID: 10575648
48. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. PMID: 18001838
49. Jones SM, Boobis AR, Moore GE, Stanier PM (1992) Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. Biochem Pharmacol 43:1876-1879. PMID: 1575782
50. Vieira I, Pasanen M, Raunio H, Cresteil T (1998) Expression of CYP2E1 in human lung and kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacol Toxicol 83:183-187. PMID: 9834965
51. Lee JE, Kang MS, Park MH, Shim SH, Yoon TK, Chung HM, et al. (2010) Evaluation of 28 human embryonic stem cell lines for use as unrelated donors in stem cell therapy: implications of HLA and ABO genotypes. Cell Transplant 19:1383-1395. doi: 10.3727/096368910X513991 PMID: 20587141
52. Cai J, Zhao Y, Liu Y, Ye F, Song Z, Qin H, et al. (2007) Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 45:1229-1239. PMID: 17464996
53. Kumaki Y, Oda M, Okano M (2008) QUMA: quantification tool for methylation analysis. Nucleic Acids Res 36:W170-175. doi: 10.1093/nar/gkn294 PMID: 18487274